Novo Nordisk has launched Awiqli, a new weekly basal insulin injection, in India. This innovative drug offers a once-weekly alternative to daily injections for diabetes patients. Awiqli aims to reduce barriers to insulin initiation, which is often delayed in India. The Indian insulin market is projected to grow significantly in the coming years. The company also competes in the growing obesity drug market within the nation.